Study of why lung cancer returns after osimertinib treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study looks at why lung cancer returns in people who took the targeted pill osimertinib after surgery. If your cancer has come back, researchers will test your tumor or blood sample to understand how the cancer changed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You had surgery to remove stage IB, II, or IIIA non-small cell lung cancer that had an EGFR mutation.
- You received the targeted therapy osimertinib (Tagrisso) after surgery, as part of your regular care.
- Your lung cancer came back while you were on osimertinib or after you finished it.
- You have a tumor sample (biopsy) or blood sample from the time your cancer returned that can be used for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a targeted therapy pill called osimertinib can work for people whose non-small cell lung cancer came back after they had surgery and completed a course of adjuvant EGFR TKI therapy (like gefitinib or erlotinib). If your cancer has an EGFR mutation and you meet the other health criteria, this trial may offer an additional treatment option.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This trial tests osimertinib (a targeted pill) given after surgery to help prevent early-stage lung cancer from coming back. It’s for people with fully removed, high-risk stage I non-small cell lung cancer that has specific EGFR gene changes.
This trial collects data from people with early-stage lung cancer that has a common EGFR mutation. After complete surgical removal of the tumor, participants take osimertinib for 3 years and are followed regularly to see how well the treatment works and why resistance might develop.
This study tests whether osimertinib can prevent remaining abnormal lung spots (called ground-glass nodules) from growing after surgery. It is for people with lung cancer caused by specific EGFR gene changes (L858R or exon 19 deletion).
This trial tests if taking osimertinib before surgery can help treat a type of non-small cell lung cancer that has specific EGFR mutations. It aims to understand how the cancer may become resistant to this targeted therapy.
Hear when a new EGFR-mutated NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.